

KISQALI® en el CMM HR+/HER2-: 5 puntos y 5 razones



KISQALI® es el único iCDK4/6 que ha demostrado supervivencia global (SG) en todos los perfiles de pacientes, independientemente de su estadio menopáusico, manteniendo o mejorando su calidad de vida.⁶⁻⁹



KISQALI® ha demostrado un beneficio clínico significativo en más del 95 % de pacientes, demostrando su eficacia en todos los subtipos intrínsecos de CMM HR+/HER2-, exceptuando el *Basal-Like* (2,6 %).¹⁰



KISQALI® prolonga la supervivencia global (SG) en subgrupos de interés clínico como las pacientes con metástasis viscerales, reduciendo un 37 % y un 47 % el riesgo relativo de muerte en función del estadio menopáusico en aquellas afectadas por metástasis hepáticas con CMM HR+/HER2-.¹¹



KISQALI®, en el ensayo ComPLEEment-1, ha confirmado su seguridad y eficacia en más de 3200 pacientes hormonosensibles tratadas en 1L en combinación con IA pertenecientes a distintos subgrupos de interés clínico.^{8,9,12}



KISQALI® es el único tratamiento para el CMM HR+/HER2- que ha demostrado el máximo beneficio clínico en 1L según la ESMO-MCBS, con una puntuación de 5 sobre 5 puntos.¹³⁻²²



1L: primera línea; **CMM:** cáncer de mama metastásico; **ESMO:** siglas del inglés *European Society for Medical Oncology*; **HER2:** siglas del inglés *human epidermal growth factor receptor 2*; **HR:** siglas del inglés *hormonal receptor*; **IA:** inhibidor de la aromatasa; **MCBS:** siglas del inglés *Magnitude of Clinical Benefit Scale*. **Referencias:** **1.** Tripathy D, et al. SABCS 2020 (PD2-04). **2.** Im SA, Lu YS, Bardia A, et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. *N Engl J Med.* 2019;381(4):307-16. **3.** Rugo HS, Finn RS, Diéras V, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. *Breast Cancer Res Treat.* 2019;174(3):719-29. **4.** Finn RS, Boer K, Bondarenko I, et al. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18). *Breast Cancer Research Treatment.* 2020;183(2):419-28. **5.** Goetz MP, Toi M, Campone M, et al. MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. *J Clin Oncol.* 2017;35(32):3638-46. **6.** Slamon DJ. ASCO (suppl 15; abstr 1001). 2021. **7.** Slamon DJ, Neven P, Chia S, et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. *J Clin Oncol.* 2018;20:36(24):2465-72. **8.** Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. *N Engl J Med.* 2016;375(18):1738-48. **9.** Tripathy D, Im SA, Colleoni M, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. *Lancet Oncol.* 2018;19(7):904-15. **10.** Prat A, Chaudhury A, Solovieff N, et al. Correlative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies. *J Clin Oncol.* 2021;1:39(13):1458-67. **11.** Yardley D, Nusch A, Yap YS, et al. Overall Survival in Patients With Advanced Breast Cancer With Visceral Metastases, Including Those With Liver Metastases, Treated With Ribociclib Plus Endocrine Therapy in the MONALEESA-3 and -7 Trials. *Poster P139.* American Society for Clinical Oncology (ASCO) Virtual Meeting 29 - 21 mayo 2020. **12.** De Laurentiis M, et al. ASCO 2020. *Poster 1055.* **13.** Slamon DJ, Neven P, Chia S, et al. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer. *N Engl J Med.* 2020;382(6):514-24. **14.** Im SA, Lu YS, Bardia A, et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. *N Engl J Med.* 2019. **15.** Fasching PA, Neven P, Esteva FJ, et al. Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib + fulvestrant: Results from MONALEESA-3. *Annals of Oncology.* 2018;29(suppl_8). **16.** Lu Y, Bardia A, Villanueva Vazquez R, et al. 308PD. Updated Overall Survival and Quality of Life in Premenopausal Patients With Advanced Breast Cancer Who Received Ribociclib or Placebo Plus Goserelin and a Nonsteroidal Aromatase Inhibitor in the MONALEESA-7 Trial. (Supplement_5). *Annals of Oncology.* 2019;30. **17.** Turner NC, Slamon DJ, Ro J, et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. *New England Journal of Medicine.* 2018;379(20):1926-36. **18.** Sledge GW, Jr., Toi M, Neven P, et al. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial. *JAMA Oncol.* 2019;1:6(1):116-24. **19.** ESMO-MCBS Scorecards. Abemaciclib. Disponible en: https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards?filterType=agent&mcbs_score_cards_form%5Btested-agent%5D=Abemaciclib. **20.** ESMO-MCBS Scorecards. Ribociclib. Disponible en: https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards?filterType=agent&mcbs_score_cards_form%5Btested-agent%5D=Ribociclib. **21.** ESMO-MCBS Scorecards. Palbociclib. Disponible en: https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards?filterType=agent&mcbs_score_cards_form%5Btumour-type%5D=Breast+Cancer. **22.** ESMO-MCBS Scorecards. Breast cancer. Disponible en: https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards?filterType=score&mcbs_score_cards_form%5Btumour-type%5D=Breast+Cancer.